Published • loading... • Updated
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Summary by mykxlg.com
3 Articles
3 Articles
mykxlg.com+2 Reposted by 2 other sources
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet
Coverage Details
Total News Sources3
Leaning Left0Leaning Right2Center1Last UpdatedBias Distribution67% Right
Bias Distribution
- 67% of the sources lean Right
67% Right
C 33%
R 67%
Factuality
To view factuality data please Upgrade to Premium
